As surgical and interventional cardiac procedures advance in both volume and complexity, clinicians will encounter an increasing number of patients who present with neurological symptoms related to a cardiac procedure. In this article, we will review the major central nervous system complications of cardiac procedures including open surgeries as well as percutaneous procedures such as percutaneous coronary interventions (PCI) and transcatheter aortic valve implantation (TAVI). As the target reader consists mainly of clinical neurologists, our focus will be on diagnosis, treatment, and secondary prevention, with a cursory discussion of primary prevention strategies.

**Incidence**

The reported incidence of perioperative stroke varies according to the type of procedure (►Table 1). Stroke occurs in 1.1 to 4.1% of patients undergoing coronary artery bypass graft (CABG) and 0.1 to 0.5% of those undergoing PCI. While many large prospective and observational studies have demonstrated that periprocedural stroke rates are lower following PCI compared with CABG, the literature is less robust for complication rates from valvular repair and replacement procedures. Registry studies of both CABG and PCI from the 2000s have reported lower incidences of periprocedural stroke compared with similar studies from the two preceding decades. However, some prospective and retrospective studies have shown either stable or even increasing rates of periprocedural stroke from the mid-1990s to the 2000s, with authors hypothesizing that advances in procedural technique are offset by the increasing proportion of high-risk patients being considered eligible for surgery.

In interpreting incidence data for perioperative stroke, one must keep in mind the high degree of heterogeneity in study type, the authors’ definition of stroke, and the method of ascertainment of stroke occurrence.

---

*S Authors contributed equally to the manuscript.*
Table 1 Incidence of stroke at 30 days by type of procedure

<table>
<thead>
<tr>
<th>Procedure type</th>
<th>Procedure</th>
<th>Incidence of periprocedural stroke (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgical</td>
<td>Isolated CABG</td>
<td>1.1–4.1</td>
</tr>
<tr>
<td></td>
<td>Combined CABG and valve</td>
<td>7.4–7.9</td>
</tr>
<tr>
<td></td>
<td>Isolated AVR</td>
<td>1.5–4.8</td>
</tr>
<tr>
<td></td>
<td>Isolated MVR</td>
<td>1.4–4.8</td>
</tr>
<tr>
<td></td>
<td>Multiple valve surgery</td>
<td>9.7</td>
</tr>
<tr>
<td></td>
<td>Aortic repair</td>
<td>4.7–7.2</td>
</tr>
<tr>
<td>Percutaneous</td>
<td>PCI</td>
<td>0.18–0.5</td>
</tr>
<tr>
<td></td>
<td>TAVI</td>
<td>2.7</td>
</tr>
</tbody>
</table>

Abbreviations: AVR, aortic valve replacement; CABG, coronary artery bypass graft; MVR, mitral valve repair; PCI, percutaneous coronary intervention; TAVI, transcatheter aortic valve implantation.

Technical aspects of the individual procedures may account for some of the differences in perioperative stroke risk. Among the myriad techniques in cardiac procedures, one of the most extensively studied is off-pump CABG (OPCABG), in which coronary anastomosis is achieved without the use of cardiopulmonary bypass. One meta-analysis of 40 randomized trials found a pooled in-hospital stroke incidence of 1.34% in the OPCABG group compared with 2.00% in the CABG group (odds ratio [OR], 0.72; 95% confidence interval [CI], 0.56–0.92; \( p = 0.009; I^2 = 0 \)%). However, none of the three largest randomized controlled trials evaluating OPCABG, each with over 2,000 subjects, found a significant reduction in the rate of in-hospital stroke. It remains controversial whether this technique in fact decreases the risk of perioperative stroke compared with conventional CABG.

Cardiac catheterization also carries a different risk of stroke depending on whether or not an intervention is performed. For example, one large single-center retrospective study examining the rate of periprocedural stroke found an incidence of 0.09% for purely diagnostic cardiac catheterizations, versus 0.23% for which an intervention such as PCI is performed.

Another procedure that deserves further discussion is TAVI, now well accepted as a less invasive alternative to surgical aortic valve replacement (AVR). Two early landmark trials using the same first-generation device found a 30-day incidence of stroke of 6.7% in patients who were not surgical candidates, and 4.6% in high-risk patients who were otherwise surgical candidates (compared with 2.4% in the surgical arm, \( p = 0.07 \)). However, subsequent trials reported substantially lower 30-day incidences of stroke, possibly attributable to improvements in device and technique, inclusion of lower risk individuals, as well as more rigorous adjudication methodology. A recent meta-analysis of 22 propensity score–matched observational studies and 6 randomized controlled trials found a 30-day rate of stroke of 2.7 and 3.1% in the TAVI and surgical AVR groups, respectively, without statistically significant difference. In recent years, cerebral embolic protection devices have emerged as a promising means to decrease the burden of both clinical and subclinical embolic infarcts resulting from TAVI. However, the clinical efficacy of these devices remains to be proven in large randomized controlled studies.

Lastly, it is important to note that the aforementioned incidence data are largely based on a clinical definition of stroke, consisting of a focal neurological deficit persisting for more than 24 hours, with or without adjudication by a neurologist. The periprocedural rate of clinically “silent” infarcts detectable on MRI is in fact many times higher than symptomatic strokes. A 2017 meta-analysis of studies in which early postprocedural MRI was performed found a staggering rate of radiographic infarcts in 27% of patients undergoing CABG and 80% of those undergoing TAVI. In the same study, the rate of radiographic infarcts was 10 times that of the combined rate of clinical strokes and transient ischemic attacks (TIAs). The cognitive consequences of silent brain infarcts will be discussed later in this article.

Timing and Mechanism

In patients who undergo CABG, less than half of perioperative strokes are identified upon awakening from anesthesia, that is, presumed to have occurred intraoperatively, whereas the remaining 55 to 63% of patients are diagnosed from the first postoperative day onward. Most strokes are apparent within the first week. A similar temporal pattern of onset has been observed with TAVI, while corresponding data for PCI are lacking and conflicting.

The large majority of strokes after cardiac procedures are ischemic as opposed to hemorrhagic. Proximal embolization from the heart or aortic arch is the most common etiology in both the intraoperative and postoperative periods. By contrast, hypoperfusion is a less common cause of stroke than most readers might expect. In a retrospective study examining etiology of 388 cases of stroke related to isolated CABG, 62.1% were determined to be embolic, and only 8.8% were deemed to be due to hypoperfusion. In the intraoperative period, embolism occurs due to release of particulate matter from manipulation of the aortic arch and heart as well as from the cardiopulmonary bypass pump. In the postoperative period, embolism occurs in the setting of increased thrombosis, including postoperative atrial fibrillation (POAF) and a general hypercoagulable state. Surgical trauma, general anesthesia, immobility, and perioperative holding of baseline antithrombotic medications all contribute to thromboembolism. Aortic plaques that were disturbed during the procedure may also cause delayed thromboembolism. However, not all periprocedural emboli are thrombotic in nature. In one study examining debris captured by an embolic protection device during TAVI, both thrombotic (73%) and tissue-derived (63%) debris were found with high prevalence. Uncommonly, a calcified embolus may be detected on noncontrast CT brain (Fig. 1).

In addition to cerebral infarction, this embolization of atherosclerotic plaque material can cause multisystem organ dysfunction, termed “cholesterol embolization syndrome.” This can occur after either endovascular or open cardiac procedures,
strokes based on a temporal correlation with hypotension, the presence of an ipsilateral high-grade vascular stenosis, as well as a characteristic pattern of distribution on imaging (Figs. 2 and 3). However, emboli may also preferentially travel to watershed zones.

Hemorrhagic strokes, which include primary intracerebral hemorrhage and subarachnoid hemorrhage, are very rare in the setting of cardiac procedures. Presumably these may be triggered by the use of high-dose antithrombotic medications in the periprocedural period in patients who are already at risk of spontaneous hemorrhagic stroke, such as those with cerebral small vessel disease, cerebral amyloid angiopathy, or unruptured aneurysms. Clinicians must be careful to avoid misdiagnosing an ischemic stroke with hemorrhagic transformation as a primary intracerebral hemorrhage. Other uncommon etiologies of stroke are listed in Table 2.

**Risk Factors**

Risk factors for stroke following cardiac procedures are listed in Table 3. Increased awareness of these risk factors can aid prevention strategies to minimize perioperative stroke risk. The most consistently reported risk factors for periprocedural stroke after cardiac procedures include female sex, previous stroke or TIA, atrial fibrillation (AF; preexisting and new onset), systolic dysfunction, and chronic renal disease. Because prior history of an ischemic cerebrovascular event is one of the strongest and most consistent predictors of periprocedural stroke, patients who have had a recent stroke or TIA should delay having any nonurgent cardiac procedures until their stroke workup and secondary prevention have been optimized.

The procedural approach also influences risk of stroke. For example, on-pump CABG is associated with a higher risk of perioperative stroke than OPCABG (beating heart CABG), though the latter is usually reserved for selected higher risk patients, due to higher technical difficulty. Predictive models for stroke risk following CABG based on readily available clinical variables have been proposed and validated.

**Risk Factors: Carotid Stenosis**

The neurologist may be asked to assess patients with known high-grade (50–99%) carotid stenosis in preparation for cardiac surgery. In these instances, it is vital to distinguish on history whether the carotid stenosis is symptomatic, which is generally defined as a history of TIA or stroke in the vascular territory of the stenotic carotid artery. Recent symptoms confer a much higher risk than remote symptoms, and many authors use a cut-off of 6 months as the window beyond which carotid artery stenosis is no longer considered “symptomatic,” though this is somewhat arbitrary. One of the few CABG outcome studies that distinguished between symptomatic and asymptomatic carotid disease found a perioperative stroke risk of 18 and 26% in unilateral and bilateral symptomatic disease, respectively.

Asymptomatic high-grade carotid stenosis, while also a risk factor for perioperative stroke, may be considered an epiphenomenon for overall atherosclerotic burden rather than a significant mechanism of periprocedural stroke. There
is no evidence to support routine prophylactic revascularization of unilateral asymptomatic carotid stenosis prior to CABG.

An additional category of carotid disease that must be considered separately is chronic carotid occlusion. While these patients have an even higher risk of perioperative stroke than those with 50 to 99% stenosis, revascularization is not advocated in chronic complete occlusion, and efforts should be directed toward other means to optimize surgical risk.

Accordingly, both American and European guidelines recommend that preoperative carotid revascularization be considered in only three instances: symptomatic high-grade stenosis, asymptomatic bilateral high-grade stenosis, or asymptomatic high-grade stenosis with contralateral carotid occlusion. Guidelines recommend against revascularization of asymptomatic unilateral carotid stenosis or stenosis <50%. Furthermore, as there is no evidence that routine preoperative screening for carotid stenosis reduces the risk of perioperative stroke, screening carotid duplex ultrasound should be limited to patients with a recent TIA or stroke, and those with high-risk features such as age >65 and known peripheral vascular disease.

In patients with concurrent high-grade carotid disease and coronary artery disease requiring revascularization, PCI would generally be favored over CABG due to its lower risk of periprocedural stroke, though other factors may make CABG the only feasible option. Carotid revascularization can be accomplished by either carotid endarterectomy (CEA) or carotid artery stenting (CAS), with equally robust evidence in isolated symptomatic carotid stenosis. No prospective

Fig. 2 An 82-year-old woman developed acute confusion 36 hours post–coronary artery bypass graft. Magnetic resonance imaging revealed punctate foci of diffusion restriction in multiple vascular territories consistent with proximal embolic “shower.” Note that although clearly embolic, some of the infarcts occur in the deep watershed zone.
studies have compared these two procedures in patients undergoing planned cardiac procedures such as CABG. The timing of carotid revascularization and CABG may be simultaneous, staged (carotid before CABG), or reverse staged (carotid after CABG). Meta-analyses of observational comparisons of staged versus simultaneous CEA or CAS with CABG do not clearly favor either timing strategy, and it should be noted that these studies included predominantly asymptomatic carotid stenosis and may be affected by inherent selection bias.  

One consideration is that following CAS, most clinicians will recommend at least 30 days of uninterrupted dual-antiplatelet therapy to prevent in-stent thrombosis. Therefore, the decision to

Fig. 3 A 73-year-old man reported mild left arm weakness and numbness immediately after percutaneous coronary intervention for a non-ST elevation myocardial infarction. He had known bilateral internal carotid artery stenosis, graded as >70% on the right and 50 to 69% on the left by ultrasound criteria. Note the classic “string of pearls” pattern of infarcts in the bilateral deep watershed zones seen on diffusion-weighted sequence (left). Also note that only some of the lesions demonstrate hypointensity on apparent diffusion coefficient sequence (right, arrow), indicating that not all are acute.

Table 2 Uncommon causes of strokes following cardiac procedures

| Air embolism from cardiopulmonary bypass and vascular access |
| Paradoxical embolism from deep vein thrombosis in patients with patent foramen ovale or atrial septal defect |
| Extracranial cervical artery dissection resulting from hyperextension of the neck during induction of anesthesia |
| Iatrogenic aortic dissection with extension into the common carotid arteries |
| Hemorrhagic stroke resulting from intraoperative heparin bolus |

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
Risk Factors: Atrial Fibrillation

Atrial fibrillation is encountered in the periprocedural period as either preexisting or new onset following the procedure, and the distinction is important for etiological attribution and management considerations.

Table 3 Risk factors for strokes following cardiac procedures

<table>
<thead>
<tr>
<th>Risk factors common to all procedures</th>
<th>Older age</th>
<th>Female sex</th>
<th>Previous stroke or TIA</th>
<th>Systolic dysfunction</th>
<th>Renal disease</th>
<th>Underweight or low body surface area</th>
<th>Left main stem coronary disease</th>
<th>Emergency presentation with acute coronary syndrome (nonelective case)</th>
<th>Carotid stenosis</th>
<th>Chronic obstructive pulmonary disease</th>
<th>Blood transfusion</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Risk factors specific to CABG</th>
<th>Non-white race</th>
<th>Preoperative atrial fibrillation</th>
<th>Peripheral vascular disease</th>
<th>Diabetes</th>
<th>Hypertension</th>
<th>Atherosclerosis of the ascending aorta</th>
<th>On-pump CABG</th>
<th>Hypothermic circulatory arrest</th>
<th>Prolonged cardiopulmonary bypass and aortic cross-clamp time</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Risk factors specific to PCI</th>
<th>PCI of an existing bypass graft</th>
<th>Hemodynamic instability</th>
<th>Intra-aortic balloon pump placement</th>
<th>Triple vessel disease</th>
<th>Presence of coronary arterial thrombus</th>
<th>Valvular disease</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Risk factors specific to TAVI</th>
<th>More severe baseline aortic regurgitation</th>
<th>Multiple device implantation attempts</th>
<th>Dislodgement of TAVI prosthesis</th>
</tr>
</thead>
</table>

Abbreviations: CABG, coronary artery bypass graft; MVR, mitral valve repair; PCI, percutaneous coronary intervention; POAF, postoperative atrial fibrillation; TAVI, transcatheter aortic valve implantation; TIA, transient ischemic attack.

*The most consistently reported risk factors are in bold.

References are listed separately below for each procedure.

Consider CAS versus CEA before CABG requires multidisciplinary discussion. In cases where revascularization is not performed, whether due to patient-specific factors in individuals with carotid stenosis or to lesions in other locations such as intracranial arterial stenoses, it is reasonable to take precautions including avoidance of significant hypotension intraoperatively, such as by setting a threshold MAP > 70 mm Hg.

In patients undergoing CABG, preexisting AF increases the risk of perioperative stroke. The type of procedure and individual thromboembolic risk must be accounted for in periprocedural antithrombotic planning. It is necessary to hold oral anticoagulation for at least several days preoperatively prior to open cardiac surgeries. Major guidelines recommend holding warfarin 5 days before major surgery with high bleeding risk, including cardiac surgeries.42–44 Bridging with low-molecular-weight heparin or unfractionated heparin should be considered for those with high thromboembolic risk, for example, those with CHADS2 score of 5 or 6.42,43 For patients on direct oral anticoagulants with normal renal function, it is recommended to hold for 48 hours before a major surgery.42,43 This duration would need to be longer in patients with reduced renal function, depending on the pharmacokinetics of each specific agent. Bridging is not indicated for direct oral anticoagulants. Although no precise recommendations are made in major guidelines regarding continuation of anticoagulation for percutaneous procedures, retrospective evidence suggests that continuous oral anticoagulant use is relatively safe in PCI and AF ablation.44–46

New-onset POAF is an important cause of perioperative stroke. It is a morbid condition independently associated with perioperative stroke in most, but not all, studies of CABG,19,32,42–51 and in both PCI and TAVI.35,52 Furthermore, POAF has adverse hemodynamic effects, is associated with higher in-hospital mortality and increased duration of hospitalization, and is a predictor of stroke occurring in the years after CABG.49,53–55 POAF occurs due to multiple factors including electrolyte imbalance, catecholamine release, atrial ischemia, and pericardial inflammation.56 Predictors of new-onset POAF are listed in Table 4. The rate of POAF is as high as 65% after combined CABG and valve surgery,57,58 Incidence is moderate after isolated CABG, ranging from 18.0 to 29.5%.53,57 The CHADS2–VASc score can be used to estimate thromboembolic risk, for example, those with CHADS2 score of 5 or 6.42,43

New-onset AF can also occur as a complication of patent foramen ovale closure for secondary stroke prevention, with an

Table 4 Predictors of new-onset postoperative atrial fibrillation

<table>
<thead>
<tr>
<th>Increasing age</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male sex</td>
</tr>
<tr>
<td>Obesity</td>
</tr>
<tr>
<td>Preoperative heart failure</td>
</tr>
<tr>
<td>Combined CABG and valve surgery</td>
</tr>
<tr>
<td>Perioperative β-blockade</td>
</tr>
<tr>
<td>Higher positive fluid balance on postoperative days 0–2</td>
</tr>
<tr>
<td>Increased white blood cell count postoperatively</td>
</tr>
<tr>
<td>Increased serum creatinine postoperatively</td>
</tr>
<tr>
<td>Low serum phosphate postoperatively</td>
</tr>
<tr>
<td>Higher serum magnesium postoperatively</td>
</tr>
<tr>
<td>Higher serum C-reactive protein postoperatively</td>
</tr>
</tbody>
</table>

Abbreviation: CABG, coronary artery bypass graft.
incidence of 0.4 to 5.0%. Current guidelines recommend the use of β-blockers as first-line primary prophylaxis for the development of POAF in patients undergoing CABG. While studies have demonstrated the efficacy of β-blockers and antiarrhythmics in the prevention of POAF, a decreased risk of perioperative stroke has not been proven.

Left atrial appendage ligation (LAAL) is frequently performed during cardiac surgical procedures in patients with preexisting AF, with the goal of long-term stroke prevention. A meta-analysis of mostly observational studies consisting of more than 280,000 patients showed significant reductions in both perioperative and long-term stroke risk, with a relative risk of 0.66 and 0.67, respectively. However, two large retrospective cohort studies suggest that this intervention may increase the risk of POAF, though they did not demonstrate an increased risk of perioperative stroke. A large randomized controlled trial is underway and is expected to complete follow-up in 2022.

Monitoring

There are multiple methods of monitoring for hypoperfusion or emboli during cardiac surgery, including near-infrared spectroscopy (NIRS), electroencephalography (EEG), and transcranial Doppler ultrasonography (TCD). Although these intraoperative monitoring techniques have some supportive evidence, they have not achieved widespread usage.

NIRS uses light emitted from a probe to evaluate the mixed (arterial and venous vessels <1 mm in diameter) vascular oxygen saturation by taking advantage of differing absorption spectra of oxyhemoglobin and deoxyhemoglobin. A systematic review of randomized controlled trials by Serraino and Murphy showed that the use of a NIRS-based protocol did not have any effect on the risk of stroke in cardiac surgery patients, with a relative risk of 1.08 (95% CI: 0.40–2.91).

EEG can also be used during cardiac surgery, and while EEG changes may be somewhat specific for acute brain injury in the setting of normal baseline EEG and stable anesthesia, EEG requires live expert interpretation to be clinically useful to detect intraoperative stroke and is not sensitive.

TCD can be used to either monitor cerebral blood flow or for the detection of microembolic signals. TCD detects cerebral microemboli as high-intensity transient signals (HITS). These microemboli indicate higher risk of concomitant macroemboli which may cause clinical stroke. The embolic risk related to TAVI has been confirmed by TCD in a study by Kahler et al, wherein intraprocedural HITS were observed in 100% of 83 patients undergoing TAVI, and these primarily occurred during manipulation of the calcified aortic valve. HITs should be interpreted with some caution, however, as they may be caused by air microbubbles rather than microemboli. This is particularly notable during PCI. Bladin et al showed that 70% of HITS during PCI occurred during injection of saline or contrast, rather than during maneuvers (such as catheter manipulation), which would be expected to cause embolic phenomena.

Postoperatively, monitoring should include continuous cardiac telemetry, particularly after CABG and open valve replacements, after which the risk of POAF is highest. Routine neurologic assessments should also be performed by nursing staff to monitor for development of neurologic deficits.

Hyperacute Stroke Management

If there is a concern for new neurologic deficit potentially representing a stroke after a cardiac procedure, hospital-specific acute stroke protocols should be activated. These should include neurological examination including the National Institutes of Health Stroke Scale confirmation of the time the patient was last known well, blood pressure and blood glucose measurements, and rapid performance of brain and cerebrovascular imaging. In centers without rapid access to stroke-trained personnel, the use of a teleneurology/telestroke system can facilitate rapid evaluation. In most centers, hyperacute imaging is best performed with noncontrast head computed tomography and computed tomographic angiography of the head and neck. In select centers, hyperacute magnetic resonance imaging (MRI) of the brain and magnetic resonance angiography of the head and neck are performed. MRI is generally not possible in the first few days after open cardiac surgeries, during which non–MRI-compatible pacing wires are frequently present.

Treatment options for suspected hyperacute stroke include thrombolysis and thrombectomy.

The AHA/ASA 2018 guidelines for the early management of acute ischemic stroke state that intravenous “alteplase is reasonable for the treatment of AIS [acute ischemic stroke] complications of cardiac or cerebral angiographic procedures, depending on the usual eligibility criteria.” Recent major surgery and coagulopathy are contraindications to intravenous thrombolysis, and most vascular neurologists would consider the risk of surgical site hemorrhage to outweigh potential benefit in the postoperative period after sternotomy. However, after percutaneous procedures, the risk of surgical site bleeding is lower, and intravenous thrombolysis can be considered. The safety of thrombolysis in patients who present with strokes after cardiac catheterization was examined in a 2008 multicenter retrospective cohort study, in which outcomes in the 12 treated patients (7 intravenous and 5 intra-arterial) compared favorably with the 54 untreated patients. It is important to keep in mind that heparinoids are frequently administered during cardiac catheterization, and after heparin administration intravenous thrombolysis should be given only if the prothrombin time has normalized. Although none of the three patients in the aforementioned cohort who were treated despite prothrombin times over 40 seconds developed a hemorrhagic complication, the AHA/ASA guidelines recommend against the use of intravenous alteplase in patients with prolonged prothrombin times.

Mechanical thrombectomy has been performed in stroke after cardiac surgery as well as catheter-based procedures and can be considered within 24 hours of postoperative stroke onset on a case-by-case basis. Thrombectomy should be considered in patients with occlusions of the intracranial carotid artery, middle cerebral artery M1 segment, and in some cases and centers proximal occlusions of the M2
branches of the middle cerebral artery. In selected cases, mechanical thrombectomy may be performed for occlusions of the basilar or posterior cerebral arteries. Patients with a large vessel occlusion who are not currently at a thrombectomy-capable center should be transferred immediately to a thrombectomy-capable center. Thrombectomy can be performed in patients with a large vessel occlusion without additional imaging beyond a noncontrast CT (to rule out hemorrhage) if it is within 6 hours of the time last known well. Patients who were last known well 6 to 24 hours before thrombectomy should undergo additional specialized imaging with CT or MR perfusion imaging, and anticoagulant performed if the patients meet the DAWN (6–24 hours) or DEFUSE-3 (6–16 hours) eligibility criteria. The DAWN criteria require a clinical-imaging mismatch with varying cut-offs for maximum core infarct volume based on age and clinical stroke severity. The DEFUSE-3 criteria require core infarct volume <70 mL, ratio of ischemic tissue to core infarct of ≥1.8, and penumbra of larger than 15 mL.

**Secondary Prevention**

For patients with perioperative stroke and no indication for anticoagulation, antiplatelet therapy is the mainstay of treatment. As long as at least a single antiplatelet agent is administered, it is reasonable to defer the choice of antiplatelet therapy to cardiology/cardiac surgical teams, though risk of hemorrhagic conversion should be weighed against thrombotic risk, particularly if dual-antiplatelet therapy is being considered.

For patients with perioperative stroke and an indication for anticoagulation, the timing of resumption of anticoagulation must be weighed carefully. Risk of recurrent stroke must be balanced against the risk of surgical bleeding and risk of hemorrhagic conversion of the stroke. American and European guidelines recommend restarting anticoagulation for AF within 14 days of stroke, but the timing of resumption within that 14-day range is unclear. The American Heart Association/American Stroke Association 2018 guidelines recommend starting oral anticoagulation between 4 and 14 days after stroke. The European Heart Rhythm Association provides more concrete guidance based on clinical stroke severity via the National Institutes of Health Stroke Scale score, with recommended oral anticoagulant resumption timelines varying from 1 to 12 days after stroke. These guideline recommendations are based on observational data and expert opinion; as to date, there have not been large randomized controlled trials addressing this issue. Regardless of the timing of initiation of anticoagulation, for patients with strokes at higher risk of hemorrhagic conversion, it is often prudent to initially use intravenous anticoagulant infusions such as unfractionated heparin rather than oral anticoagulation given the ability to quickly reverse the agent if hemorrhage does occur. If the patient demonstrates clinical and/or imaging stability on intravenous anticoagulation, and with increased time since infarction, clinicians can then consider transitioning to the oral anticoagulant of choice.

Whether or not patients with preoperative AF who undergo LAAL should resume anticoagulation is currently unknown. Exclusion of the left atrial appendage is not always complete, with success rate for occlusion by postoperative transesophageal echocardiography ranging from 66 to 95%. Historically, new-onset POAF was considered a short-term complication that did not result in serious morbidity or mortality. While POAF onset peaks on postoperative days 2 to 3 with a median duration of 22 hours, and indeed often is (at least initially) transient with only 2.8% of POAF patients having persistent AF on discharge, it is associated with significant long-term consequences.

Butt et al showed in a cohort of patients with left-sided valvular surgery that POAF patients were similarly likely to be initially treated with oral anticoagulants compared with new-onset nonvalvular atrial fibrillation (NVAF) patients, but POAF patients were less likely to still be taking oral anticoagulants at 1 year compared with NVAF patients. Though they were less likely to be on oral anticoagulants at 1 year, patients with POAF had similar risk of thromboembolism as NVAF (HR: 1.22; 95% CI: 0.88–1.68). This similar thromboembolic risk is not mediated by recurrent AF, as POAF patients after all types of cardiac surgery had lower risk of recurrent AF compared with NVAF (HR: 0.62; 95% CI: 0.56–0.70), but the subset of patients who underwent mitral valve surgery had similar risk of recurrent AF when compared with NVAF patients. While this discrepancy between rates of recurrent AF and thromboembolism may represent subclinical short AF events, it is not clear why subclinical events would not be equally prevalent in both groups. It is therefore possible that POAF indicates the presence of an atrial cardiopathy that itself increases thromboembolic risk.

Multiple major international guidelines have addressed the question of antithrombotic management of POAF. The American Heart Association/American College of Cardiology/Heart Rhythm Society guidelines state it is reasonable to consider antithrombotic therapy for POAF patients just as would be done for patients with AF of other etiologies. The European Heart Rhythm Association’s guidelines recommend consideration of antithrombotic therapy if the duration of POAF is at least 48 hours. The Canadian Cardiovascular Society recommends consideration of anticoagulation if POAF lasts at least 72 hours and is present at hospital discharge, and recommends reexamination of the anticoagulation decision at 6 to 12 weeks postoperatively.

**Cognitive Complications**

Cardiac surgeries result in both acute and chronic cognitive complications. Both early and late cognitive complications are more common after open cardiac surgeries, though they can occur in catheter-based procedures as well. Early postoperative cognitive dysfunction is likely caused by contributions from embolism, hypoperfusion injury, blood–brain barrier injury from systemic inflammation, as well as toxic–metabolic encephalopathy and ICU delirium. The presence of late cognitive decline implies that some permanent cerebral injury occurs in the perioperative period.
The argument for cerebral hypoperfusion as a contributing factor in early perioperative cognitive dysfunction is supported by a study of 92 patients by Siepe et al. This study showed that increased systemic perfusion pressure (mean arterial pressure of 80–90 compared with 60–70) during cardiopulmonary bypass was associated with reduced risk of postoperative delirium. This association was present despite a lack of difference between groups in intraoperative cerebral oxygenation as measured by NIRS. Another putative causative factor, systemic inflammation, has been demonstrated postoperatively, but there are currently no treatments that have consistently shown benefit on this mechanism.

There is some limited evidence for modulating sympathetic activity in preventing acute cognitive dysfunction after cardiac surgery; perioperative dexmedetomidine was shown to be beneficial in reducing postoperative delirium (adjusted OR: 0.350; 95% CI, 0.212–0.578).

Embolic ischemic cerebral injury is a clear contributor to both acute and chronic neurocognitive dysfunction. Embolic appearing diffusion-restricting brain lesions on MRI are very common after cardiac procedures, particularly after CABG and valve surgeries (both open and transcatheter). The incidence of new cerebral ischemic lesions on MRI ranges from 31 to 40% open cardiac surgery, and as high as 90% after TAVI. Barber et al showed cognitive dysfunction at 5 days and 6 weeks postoperatively in 15 of 15 patients with new ischemic brain lesions (the majority of which were silent) versus only 6 of 17 patients without new ischemic lesions (p < 0.001).

While silent ischemic lesions are associated with cognitive decline, intraoperative embolic signals detected by TCD have not been similarly correlated with early cognitive dysfunction; however, they may play a greater role in chronic cognitive dysfunction. Using intraoperative TCD microembolic signals, Liu et al showed that microembolic signals were reduced from a median of 430 to 2 when comparing surgery with cardiopulmonary bypass and off-pump surgery, but there was no difference in the incidence of postoperative cognitive dysfunction between the two surgical techniques at either 1 week or 3 months. This lack of early difference with microemboli reduction with OPCABG was corroborated in a similar study by Stroobant et al., though the off-pump group demonstrated cognitive impairment on fewer neuropsychological tests 6 months postoperatively.

Silent cerebral microbleeds have also been identified postoperatively after cardiac surgery. A study by Patel et al showed a 24% incidence of new cerebral microbleeds, and there was a linear association with longer time on cardiopulmonary bypass, but there was no association with cognitive outcomes.

The time course of chronic postoperative cognitive decline raises questions about its mechanisms. There is not only a step-off from baseline cognition after surgery, as would be expected from pure perioperative ischemic injury, but also progressive postsurgical decline. Newman et al performed a battery of neurocognitive tasks at preoperative, in-hospital, 6-week, 6-month, and 5-year time points. In both patients who were and who were not cognitively impaired at discharge, cognition improved postoperatively, peaking at the 6-month time point, and then decreased again at the 5-year time point. Though both groups followed this same general trajectory over time, the group without cognitive decline prior to discharge returned to baseline cognition at 6 months, whereas those with cognitive decline prior to discharge did not. Those with cognitive decline prior to discharge also had a more severe drop in cognition between the 6-month and 5-year evaluations. It is unclear whether this accelerated cognitive decline seen in some patients post-cardiac surgery reflects the presence of an underlying neurodegenerative disorder, or whether the surgery itself unmasks or accelerates cognitive decline. This determination is confounded by the presence of vascular risk factors, which are prevalent in both patient populations who undergo cardiac surgery and those who develop dementia. There are currently no large studies with appropriate control arms to determine whether the rate of progressive cognitive decline after cardiac surgery is different than would be expected in this patient population with vascular risk factors.

Lastly, it is possible that for some patients, improved cerebral blood flow and quality of life may in fact contribute to better cognitive function after cardiac procedures. One prospective cohort study trended an extensive battery of cognitive tests in 51 patients undergoing TAVI and found an average improvement in the cognitive status persisting at 1 year, though unfortunately no imaging data were available to correlate individual cognitive trajectories with silent ischemic lesions.

Other Neurological Complications of Cardiac Procedures

Contrast-Induced Encephalopathy

Contrast-induced encephalopathy is a rare but well-recognized complication of cardiac catheterization and other angiographic procedures. Symptom onset is within minutes to hours of iodinated contrast exposure, and can include any combination of headache, encephalopathy, cortical blindness and other focal cortical symptoms, and seizure. Risk factors include renal disease, higher contrast load, and the use of older, ionic, high osmolality contrast preparations. Neuroimaging may be normal or may show vasogenic edema and cortical contrast enhancement with a posterior predilection. The pathophysiology of contrast-induced encephalopathy involves endothelial dysfunction and failure of autoregulation. This pathophysiology has a high degree of overlap with the posterior reversible encephalopathy syndrome (PRES). Like PRES, contrast-induced encephalopathy is usually fully reversible within days with supportive management alone.

Seizures

Seizures may rarely be provoked in the setting of cardiac procedures by a variety of factors such as acute stroke, medications, contrast-induced encephalopathy, or hypoxic brain injury. Furthermore, patients with preexisting epilepsy may experience breakthrough seizures in the postprocedural period. In a large single-center study of consecutive CABG cases, postoperative seizures occurred in 0.95% of patients.
Median time of first seizure from the completion of surgery was 6 hours, 59% were generalized, and 14.5% were associated with a new stroke on imaging. Seizures were associated with longer ICU stays and higher ICU mortality.\textsuperscript{107} Nonconvulsive seizures, including nonconvulsive status epilepticus, should be considered when evaluating patients who do not awake after cardiac surgery. In these patients, EEG evaluation is critical, ideally by performing 24 hours of continuous EEG monitoring to rule out intermittent nonconvulsive seizures.

One important cause of provoked seizures in patients undergoing open cardiac surgeries is the use of high-dose tranexamic acid, an antifibrinolytic medication with known dose-related proconvulsant properties. In the Aspirin and Tranexamic Acid for Coronary Artery Surgery trial, patients undergoing CABG who were randomized to receive 50 to 100 mg/kg of tranexamic acid were 7.6 times more likely to have a postoperative seizure compared with the placebo group, with a number needed to harm of 177.\textsuperscript{108}

Seizures following cardiac procedures, especially open cardiac surgeries, should be aggressively treated with antiseizure medications, which should be continued for at least the postoperative period, and longer depending on underlying cause.

**Conclusion**

Neurologic complications, particularly acute ischemic stroke and encephalopathy, are common after cardiac procedures. Neurologists play an important role in diagnosing, treating, and directing secondary prevention strategies for these conditions, and should maintain familiarity with both common and uncommon complications of cardiac procedures. Given the complexity of these complications and the heterogeneity of available evidence, it is important to individualize each patient’s management plan and coordinate multidisciplinary communication to ensure optimal patient care.

**Conflict of Interest**

None declared.

**References**


Seminars in Neurology Vol. 41 No. 4/2021 © 2021. Thieme. All rights reserved.
Neurological Complications of Cardiac Procedures


51 Lofth A, Wartak S, Sethi P, Garb J, Giuggiano GR. Postoperative atrial fibrillation is not associated with an increased risk of stroke or the type and number of grafts: a single-center retrospective analysis. Clin Cardiol 2011;34(12):787–790


56 Burke SW, Solomon AJ. Atrial fibrillation in patients after cardiac vascular surgery: incidence, risk factors, preventive and therapeutic strategies. Am J Cardiovascular Drugs 2003;3(02):95–100


94 Siepe M, Pfeiffer T, Gieringer A, et al. Increased systemic perfusion pressure during cardiopulmonary bypass is associated with...
97 Barber PA, Hach S, Tippett L, Ross L, Merry AF, Millsom P. Cerebral ischemic lesions on diffusion-weighted imaging are associated with neurocognitive decline after cardiac surgery. Stroke 2008;39(05):1427–1433